To meet the immediate need for testing and help save lives, Boston BioPharm partnered with GeneMatrix, under an exclusive license and technology transfer for the NeoPlexTM line of diagnostic products, in North & South America and Europe.
Our partner GeneMatrix was founded in December 2000 and is a global biotechnology leader in the field of molecular diagnostics. They have developed and own numerous patented molecular diagnostic technologies such as C-TAG, Omniplex, EnCleap, TriO & REMP which have been applied to Hepatitis B and C, cervical cancer, sexually transmitted infections, gastrointestinal infections and respiratory infections including influenza.
Together, GeneMatrix and Boston BioPharm pioneered an approved KFDA, FDA, CE-IVD NeoPlexTM Covid-19 Detection Kit with clinical detection results shown to be 100% accurate.
About NeoPlex/Patent-Protected Technology:
NeoPlexTM Covid-19 Detection Kit (100% Accuracy/FDA IFU), nucleic acid extraction/analysis (molecular test). Regulatory Status: FDA EUA Approved (EUA200803 authorization number) KFDA, and EU-IVD
Compatible with all Real-Real Time PCR (96 & 384 well plate) and automatic extraction Instruments:- 100% Accurate Testing Results unlike most tests (see FDA IFU Document)
(EUA for Molecular Diagnostic Tests for SARS-CoV-2)
Please reach out to us with any special requests.
550 Reserve Street, Southlake, Texas 76092, United States
Monday - Friday: 9am - 5pm
Saturday - Sunday: Closed